BioSpace News Archive

Cybin Inc. today announced the launch of the EMBARK Psychedelic Facilitator Training Program.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that its patent titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation” has been granted in Hong Kong and Mexico, and has received a notice of allowance in Japan.

Intellia Therapeutics, Inc. will present its third quarter 2021 financial results and operational highlights in a conference call on November 4, 2021 at 8 a.m. ET.

Alimera Sciences, Inc. today announced financial results for the third quarter of 2021. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Eton Pharmaceuticals, Inc today announced that it has acquired U.S. marketing rights to carglumic acid tablets.

Aerie Pharmaceuticals, Inc. announced today that its third quarter 2021 financial results will be released after the market closes on Thursday, November 4, 2021.

Repligen Corporation today reported financial results for its third quarter of 2021.

Incyte (Nasdaq:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream

Revolo Biotherapeutics (“Revolo Bio” or the “Company”), announced today that it has activated clinical trial sites and opened enrollment in a Phase 2 clinical trial evaluating their first-in-class peptide for the treatment of allergic diseases, ‘1104, in patients with eosinophilic esophagitis (EoE).

Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.